Loading...
Does TMB impact the effectiveness of TKIs in EGFR-mutant NSCLC?
Patients with EGFR-mutant NSCLC achieve variable benefit from targeted therapy, and biomarkers to predict degree of benefit are not in clinical use. EGFR-mutant cancers with high tumor mutational burden demonstrate poorer outcomes on EGFR targeted therapy. Investigation into the mechanisms underlyin...
Na minha lista:
| Udgivet i: | Clin Cancer Res |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6359945/ https://ncbi.nlm.nih.gov/pubmed/30190372 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-2368 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|